Browsing Tag
Carlos Vargas
1 post
Syncromune targets broader oncology opportunities with proprietary tumor-directed immunotherapy technology
Syncromune's SYNC-T reports 80% two-year prostate cancer survival as its Phase 2a trial expands. Explore commercial potential and risks.